Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Diseases, Beijing 100050, China.
Department of Gastroenterology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
Infect Genet Evol. 2020 Nov;85:104443. doi: 10.1016/j.meegid.2020.104443. Epub 2020 Jun 30.
Japanese encephalitis virus (JEV) is the causal pathogen of Japanese encephalitis (JE), which has become a severe public health problem and is one of the most rapidly spreading mosquito-borne diseases worldwide. Currently, there is no specific treatment for JEV. A vaccine would be an effective measure for reducing morbidity and mortality. Although the live attenuated vaccine SA14-14-2 has been approved in some countries, it is still necessary to develop safer, more effective, and less costly vaccines. In this study, a DNA vaccine candidate, pV-SA14ME, expressing the prM/E proteins of SA14-14-2 was inoculated into BALB/c mice via intramuscular electroporation, and the immunogenicity and degree of protection were evaluated. We found that administration of 50 μg pV-SA14ME via electroporation via three immunizations could induce persistent humoral and cellular immune responses and effectively protect mice against lethal JEV challenge. This study provides a basis for the subsequent promotion and use of the vaccine and lays the foundation for its further use in swine and humans.
日本脑炎病毒（JEV）是日本脑炎（JE）的病原体，已成为严重的公共卫生问题，也是全球传播最快的蚊媒疾病之一。目前，尚无针对 JEV 的特效治疗方法。疫苗将是降低发病率和死亡率的有效措施。虽然减毒活疫苗 SA14-14-2 已在一些国家获得批准，但仍需要开发更安全、更有效且成本更低的疫苗。本研究构建了表达 SA14-14-2 株 prM/E 蛋白的 DNA 疫苗候选株 pV-SA14ME，并通过肌肉电穿孔免疫 BALB/c 小鼠，评价其免疫原性和保护效果。结果表明，3 次肌肉电穿孔免疫 50μg pV-SA14ME 可诱导持久的体液和细胞免疫应答，并有效保护小鼠免受致死性 JEV 攻击。本研究为疫苗的后续推广和应用提供了依据，为其在猪和人类中的进一步应用奠定了基础。
